ADT Use Not Linked to Dementia in Prostate Cancer

Excerpt:

“For men with prostate cancer, use of androgen deprivation therapy (ADT) seems not to be associated with dementia, according to a study published online Nov. 21 in the Journal of Clinical Oncology.

“Farzin Khosrow-Khavar, Ph.D., from McGill University in Hamilton, Canada, and colleagues examined whether use of ADT is associated with increased risk of dementia, including Alzheimer’s disease. A cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer from April 1, 1988, to April 30, 2015 were recruited and followed until April 30, 2016. To account for delays associated with dementia diagnosis and minimize reverse causality, ADT exposure was lagged by one year.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Psychological Effects From ADT a Growing Challenge in Prostate Cancer

Excerpt:

“Androgen-deprivation therapy (ADT) can be associated with significant psychological effects in patients with prostate cancer.

“Additionally, these side effects—which include depression, Alzheimer disease, and coronary disease—are often underreported by patients, according to Heather Jim, MD.

“ ‘It is really important for the clinician to let [patients] know that a lot of men experience this. Let’s get them help and try to help them feel better,’ said Jim, who discussed these significant events in her lecture at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.”

Go to full article.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.


Hormone Therapy for Prostate Cancer Tied to Possible Alzheimer's Risk

“Hormone therapy for prostate cancer might dramatically increase a man’s risk of developing Alzheimer’s disease, a large-scale analysis of health data suggests.

“Men who underwent  (ADT) for their prostate cancer had nearly twice the risk of Alzheimer’s, when compared to prostate cancer patients who didn’t receive hormone therapy, researchers found.

“The risk increased even more if men received hormone therapy for longer than a year, said study lead author Dr. Kevin Nead, a radiation oncology resident at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia.”